Boll Björn, Bessa Juliana, Folzer Emilien, Ríos Quiroz Anacelia, Schmidt Roland, Bulau Patrick, Finkler Christof, Mahler Hanns-Christian, Huwyler Jörg, Iglesias Antonio, Koulov Atanas V
Analytical Development & Quality Control, Pharma Technical Development Biologics Europe, F. Hoffmann-La Roche Ltd. , Basel, Switzerland.
Division of Pharmaceutical Technology, Department of Pharmaceutical Sciences, University of Basel , Basel, Switzerland.
Mol Pharm. 2017 Apr 3;14(4):1292-1299. doi: 10.1021/acs.molpharmaceut.6b00816. Epub 2017 Mar 7.
A current concern with the use of therapeutic proteins is the likely presence of aggregates and submicrometer, subvisible, and visible particles. It has been proposed that aggregates and particles may lead to unwanted increases in the immune response with a possible impact on safety or efficacy. The aim of this study was thus to evaluate the ability of subvisible particles of a therapeutic antibody to break immune tolerance in an IgG1 transgenic mouse model and to understand the particle attributes that might play a role in this process. We investigated the immunogenic properties of subvisible particles (unfractionated, mixed populations, and well-defined particle size fractions) using a transgenic mouse model expressing a mini-repertoire of human IgG1 (hIgG1 tg). Immunization with proteinaceous subvisible particles generated by artificial stress conditions demonstrated that only subvisible particles bearing very extensive chemical modifications within the primary amino acid structure could break immune tolerance in the hIgG1 transgenic mouse model. Protein particles exhibiting low levels of chemical modification were not immunogenic in this model.
目前对于治疗性蛋白质使用的一个关注点是可能存在聚集体以及亚微米级、亚可见和可见颗粒。有人提出,聚集体和颗粒可能会导致免疫反应意外增强,进而可能影响安全性或疗效。因此,本研究的目的是评估治疗性抗体的亚可见颗粒在IgG1转基因小鼠模型中打破免疫耐受的能力,并了解可能在此过程中起作用的颗粒属性。我们使用表达人IgG1(hIgG1 tg)微型库的转基因小鼠模型,研究了亚可见颗粒(未分级、混合群体以及明确粒径分级)的免疫原性。用人工应激条件产生的蛋白质亚可见颗粒进行免疫表明,只有在一级氨基酸结构内具有非常广泛化学修饰的亚可见颗粒才能在hIgG1转基因小鼠模型中打破免疫耐受。在该模型中,化学修饰水平低的蛋白质颗粒没有免疫原性。